These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15875078)

  • 1. Inhibitors of proteases as anticancer drugs.
    Jedinak A; Maliar T
    Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
    Masson V
    Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors.
    Banke IJ; Arlt MJ; Pennington C; Kopitz C; Steinmetzer T; Schweinitz A; Gansbacher B; Quigley JP; Edwards DR; Stürzebecher J; Krüger A
    Biol Chem; 2003; 384(10-11):1515-25. PubMed ID: 14669995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic urokinase inhibitors as potential antitumor drugs.
    Steinmetzer T
    IDrugs; 2003 Feb; 6(2):138-46. PubMed ID: 12789617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
    Persky B; Ostrowski LE; Pagast P; Ahsan A; Schultz RM
    Cancer Res; 1986 Aug; 46(8):4129-34. PubMed ID: 3524801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cellular proteases and invasion].
    Roessner A; Krüger S; Kido A
    Verh Dtsch Ges Pathol; 2000; 84():69-76. PubMed ID: 11217451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular proteases as targets for treatment of cancer metastases.
    Lee M; Fridman R; Mobashery S
    Chem Soc Rev; 2004 Sep; 33(7):401-9. PubMed ID: 15354221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
    Krol J; Sato S; Rettenberger P; Assfalg-Machleidt I; Schmitt M; Magdolen V; Magdolen U
    Biol Chem; 2003 Jul; 384(7):1085-96. PubMed ID: 12956425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
    Ostrowski LE; Ahsan A; Suthar BP; Pagast P; Bain DL; Wong C; Patel A; Schultz RM
    Cancer Res; 1986 Aug; 46(8):4121-8. PubMed ID: 3089587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local proteolytic activity in tumor cell invasion and metastasis.
    Ludwig T
    Bioessays; 2005 Nov; 27(11):1181-91. PubMed ID: 16237672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological activity and clinical implications of the matrix metalloproteinases.
    Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M
    Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro invasion assays.
    Chambers SK
    Methods Mol Med; 2001; 39():179-85. PubMed ID: 21340770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein C and its inhibitor in malignancy.
    Suzuki K; Hayashi T
    Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cathepsin family and their role in colorectal cancer.
    Kuester D; Lippert H; Roessner A; Krueger S
    Pathol Res Pract; 2008; 204(7):491-500. PubMed ID: 18573619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteine cathepsins in human cancer.
    Jedeszko C; Sloane BF
    Biol Chem; 2004 Nov; 385(11):1017-27. PubMed ID: 15576321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
    Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
    Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving role of uPA/uPAR system in human cancers.
    Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
    Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic urokinase inhibitors as potential anti-invasive drugs.
    Stürzebecher J; Schweinitz A; Schmalix WA; Wikström P
    IDrugs; 2001 Jun; 4(6):677-83. PubMed ID: 16001312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
    Skogseth H; Larsson E; Halgunset J
    APMIS; 2006 Jan; 114(1):61-6. PubMed ID: 16499663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.